A real-life retrospective monocentric cohort study of Doravirine co-formulated with tenofovir disoproxil (TDF) and lamivudine (3TC) in virologically suppressed HIV-1-infected patients
Latest Information Update: 16 Dec 2022
At a glance
- Drugs Doravirine/lamivudine/tenofovir disoproxil fumarate (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 16 Dec 2022 New trial record
- 26 Oct 2022 Results presented at the 16th International Congress on Drug Therapy and HIV Infection